In 2012 Congress enacted S. 99, the American Medical Isotopes Production Act of 2011, as part of the Defense Authorization bill. S. 99 addressed some of the technology and waste disposal issues that were obstacles to the development of new Molybdenum-99 (Mo-99) production facilities. The U.S. consumes approximately one-half of the world’s supply of Mo-99, but currently has no domestic source of supply.
On April 1, 2014, President Obama then signed H.R. 4302, the Protecting Access to Medicare Act of 2014, into law. This one-year SGR patch made permanent changes to how physicians who perform advanced imaging services are paid by connecting it to appropriate use criteria. These changes state that Secretary of Health and Human Services must launch (by 2017) a program that encourages the use of AUCs for advanced diagnostic imaging services (ADIS). Additionally, no later than November 15, 2015, the Secretary, in consultation with stakeholders, will choose which AUCs will be included in the program.
Some nuclear pharmacies compound certain radiopharmaceuticals and adjunct drugs, especially during times of shortages, after discontinuation by the manufacturer not related to safety issues, and for other reasons. On September 28, 2013, the House of Representatives approved a new bill, H.R. 3204, the Drug Quality and Security Act. The Senate also passed H.R. 3204 by voice vote on November 18. President Obama signed the bill on November 27 as Public Law No: 113-54.
On January 17, 2014, President Obama signed H.R.3547, the Consolidated Appropriations Act, also known as the $1 trillion omnibus spending bill, into law. The Energy and Water Development Appropriations Explanatory Statement includes $5 million to continue nuclear medicine research with human applications and is administered by the Office of Biological and Environmental Research at the Department of Energy.
SNMMI also deals with various other legislative issues.